AB0763 SAFETY OF ABATACEPT TREATMENT OVER 2 YEARS IN A PHASE III ACTIVE PSORIATIC ARTHRITIS RANDOMIZED TRIAL (ASTRAEA)

MLA

Alice B. Gottlieb, et al. “Ab0763 Safety of Abatacept Treatment over 2 Years in a Phase Iii Active Psoriatic Arthritis Randomized Trial (Astraea).” Abstracts Accepted for Publication, June 2019. EBSCOhost, https://doi.org/10.1136/annrheumdis-2019-eular.344.

APA

Alice B. Gottlieb, Dafna D. Gladman, Subhashis Banerjee, Oliver FitzGerald, Harris A. Ahmad, Alyssa Johnsen, Désirée van der Heijde, Philip J. Mease, & Marleen Nys. (2019). Ab0763 Safety of Abatacept Treatment over 2 Years in a Phase Iii Active Psoriatic Arthritis Randomized Trial (Astraea). Abstracts Accepted for Publication. https://doi.org/10.1136/annrheumdis-2019-eular.344

Chicago

Alice B. Gottlieb, Dafna D. Gladman, Subhashis Banerjee, Oliver FitzGerald, Harris A. Ahmad, Alyssa Johnsen, Désirée van der Heijde, Philip J. Mease, and Marleen Nys. 2019. “Ab0763 Safety of Abatacept Treatment over 2 Years in a Phase Iii Active Psoriatic Arthritis Randomized Trial (Astraea).” Abstracts Accepted for Publication, June. doi:10.1136/annrheumdis-2019-eular.344.